Population pharmacokinetic analysis during the first 2 years of life: an overview.
about
Developmental pharmacokinetics in pediatric populationsPaediatric pharmacokinetics and drug dosesPopulation pharmacokinetics of gentamicin and dosing optimization for infantsSpecial population considerations and regulatory affairs for clinical researchPharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures.Pharmacokinetic studies in infants using minimal-risk study designsClinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.Methods for pharmacokinetic analysis in young children.Ethics of drug research in the pediatric intensive care unit.Ethics of drug studies in the newborn.Prediction of drug clearance in children.Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future.Theophylline: a review of population pharmacokinetic analyses.Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children.Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.High-dose gentamicin in newborn infants: is it safe?Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants.Steady-state pharmacokinetics of oral linezolid suspension in a premature infant with osteomyelitis.
P2860
Q27002933-067ACDAB-6F7B-42DA-B093-F78D6C8CC7D5Q28078794-CA12D178-22A4-4211-A2B2-2DDDF78113EAQ34923469-0DA9C4EF-4859-45CD-97AB-AF3A73063344Q36078698-9B3B0A5C-1852-4E0F-818C-D957A53C8FB6Q36113640-8EA6FC8C-7E67-4E6A-8784-7B3C0D1510E3Q36438116-9F986998-80CE-4D1A-A5A0-60212E349565Q36730100-B0FFC03D-B0DA-4B17-AE5F-9AE58B26897EQ38187157-3AAC7D93-C032-402D-BFFD-6D0FE787AD21Q38263726-CA3592CE-89C4-4D07-A5DE-E50FB87D314DQ38263730-C80009DF-4C72-42E0-A83B-BC5530FE0DD8Q38365645-25138B27-84EB-44F5-811F-BC648BBD70EAQ38563371-57BBA7FF-7F32-443A-BD8D-FD1BA573C4F6Q38804930-9E155812-9F01-4FA7-9845-58A1DDC0B717Q38857191-37980B4A-D726-490B-92E3-93B0F14DF9CFQ44781273-DBBC3DA0-E852-43B8-B38B-78A7EF369602Q47600971-DD904DCA-F0AF-4908-BBC3-3319B41EB835Q50356292-C565A5E7-2D8C-49BA-A3C1-8EAE01AA0787Q50468318-DAF3DB61-3BD1-4667-B612-41B60952D8C3Q54668056-82175301-0642-48DC-83DF-CB0EF9FDA36B
P2860
Population pharmacokinetic analysis during the first 2 years of life: an overview.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Population pharmacokinetic analysis during the first 2 years of life: an overview.
@en
type
label
Population pharmacokinetic analysis during the first 2 years of life: an overview.
@en
prefLabel
Population pharmacokinetic analysis during the first 2 years of life: an overview.
@en
P2093
P2860
P1476
Population pharmacokinetic analysis during the first 2 years of life: an overview
@en
P2093
Amélie Marsot
Audrey Boulamery
Bernard Bruguerolle
P2860
P2888
P304
P356
10.1007/S40262-012-0015-8
P577
2012-12-01T00:00:00Z
P5875
P6179
1030633347